Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Drooling treatment shows promise in Late-Stage trial

NCT ID NCT01994109

First seen Apr 24, 2026 · Last updated May 12, 2026 · Updated 4 times

Summary

This study tested an injected medication called MYOBLOC to reduce troublesome drooling in 187 adults. Drooling can be a side effect of many health conditions. The treatment was injected directly into the salivary glands and was shown to safely decrease saliva production. The goal was to improve comfort and quality of life for people bothered by excessive drooling.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SIALORRHEA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Study site

    Loma Linda, California, 92354, United States

  • Study site

    Los Angeles, California, 90033, United States

  • Study site

    National City, California, 91950, United States

  • Study site

    Aurora, Colorado, 80045, United States

  • Study site

    Washington D.C., District of Columbia, 20007, United States

  • Study site

    Boca Raton, Florida, 33486, United States

  • Study site

    Port Charlotte, Florida, 33980, United States

  • Study site

    Carmel, Indiana, 46032, United States

  • Study site

    Baltimore, Maryland, 21287, United States

  • Study site

    Elkridge, Maryland, 21075, United States

  • Study site

    Detroit, Michigan, 48334, United States

  • Study site

    St Louis, Missouri, 63110, United States

  • Study site

    Edison, New Jersey, 08818, United States

  • Study site

    Albany, New York, 12208, United States

  • Study site

    New York, New York, 10003, United States

  • Study site

    Cincinnati, Ohio, 45219, United States

  • Study site

    Tulsa, Oklahoma, 74136, United States

  • Study site

    Port Royal, South Carolina, 29935, United States

  • Study site

    Cordova, Tennessee, 38018, United States

  • Study site

    Houston, Texas, 77030, United States

  • Study site

    San Antonio, Texas, 78229, United States

  • Study site

    Salt Lake City, Utah, 84132, United States

  • Study site

    Kirkland, Washington, 98034, United States

  • Study site

    Tacoma, Washington, 98409, United States

  • Study site

    Irkutsk, Irkutsk Oblast, 664079, Russia

  • Study site

    Vsevolozhsk, Leningradskaya Oblast', 188643, Russia

  • Study site

    Saint Petersburg, Petrodvorets, 198510, Russia

  • Study site

    Krasnoyarsk, 660037, Russia

  • Study site

    Dnipropetrovsk, 49027, Ukraine

  • Study site

    Ivano-Frankivsk, 76008, Ukraine

  • Study site

    Kharkiv, 61068, Ukraine

  • Study site

    Lviv, 79010, Ukraine

  • Study site

    Rivne, 33010, Ukraine

  • Study site

    Uzhhorod, 88018, Ukraine

Conditions

Explore the condition pages connected to this study.